In our study, we observed downregulation of sPD-L2 with other soluble immune inhibitory markers such as sTIMD4, sNectin2, and CEA indicating the plausibility of a synergistic mechanism of soluble markers with each other thus enabling anti-tumor response in high tissue PD-L1 expressing patients. The gene discussed is CEACAM5; the disease is neoplasm.